KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), a pioneer in drug delivery platforms, announced the acquisition of two significant patents, further expanding its intellectual property portfolio. The new patents pertain to the treatment of hypertension and epilepsy, with the company now holding 43 granted patents globally.
The first patent, within Lexaria's patent family #21, covers Compositions and Methods for Treating Hypertension. This patent is the third U.S. grant in this category. Lexaria's proprietary technology, DehydraTECH-processed cannabidiol (CBD), has shown potential in reducing blood pressure in hypertensive subjects both after acute dosing and over a five-week study period. This patent is set to expire in 2042, subject to extensions.
The second patent falls under Lexaria's patent family #24 and addresses Compositions and Methods for Treating Epilepsy. It represents the third U.S. patent grant in this field. The technology has been recognized for its ability to mitigate epileptic seizures in rodents and for its enhanced absorption into the bloodstream compared to Epidiolex®, a commercially available cannabinoid-based anti-seizure medication. This patent is also expected to expire in 2042 unless extended.
Lexaria's DehydraTECH technology is a patented drug delivery formulation that has been shown to improve the bio-absorption of active pharmaceutical ingredients (APIs) through oral delivery. The technology has been under development since 2016 and has demonstrated increased bio-absorption and the potential for more effective delivery of some drugs across the blood-brain barrier. This could be particularly significant for treatments involving centrally active compounds.
The company maintains a robust intellectual property portfolio with many patents pending worldwide in addition to the granted ones. Lexaria operates a licensed in-house research laboratory, which plays a crucial role in supporting the company's future business objectives.
It is worth noting that the company's press release contains forward-looking statements which are based on current information and come with risks and uncertainties. These include the company's ability to conduct research, receive regulatory approvals, and achieve the anticipated positive outcomes from its studies. The information in this article is based on a press release statement from Lexaria Bioscience Corp.
InvestingPro Insights
As Lexaria Bioscience Corp. (NASDAQ:LEXX) continues to expand its intellectual property portfolio with the acquisition of new patents, investors and industry watchers are keeping a close eye on the company's financial health and market performance.
According to InvestingPro data, Lexaria holds a market capitalization of $37.11 million USD. Despite not being profitable over the last twelve months, the company has seen a significant 23.16% revenue growth for the same period.
InvestingPro Tips for Lexaria point out that the company holds more cash than debt on its balance sheet, which is a positive sign for financial stability. Analysts also anticipate sales growth in the current year, although they do not expect the company to be profitable this year.
While Lexaria is trading at a high Price / Book multiple of 5.77, it has demonstrated a strong return over the last year with a 288.61% price total return, highlighting a potential investor confidence in its growth trajectory.
For those interested in a deeper dive into Lexaria's financial metrics and future outlook, there are additional InvestingPro Tips available at https://www.investing.com/pro/LEXX. These tips could provide valuable insights, especially considering the company's recent patent acquisitions and the potential of its DehydraTECH technology.
Investors can access these insights and more by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 11 more InvestingPro Tips listed in InvestingPro, there's a wealth of information to help make informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.